Epidemiological, clinical features and susceptibility pattern of shigellosis in the buea health district, Cameroon

<p>Abstract</p> <p>Background</p> <p>Shigellosis is an acute invasive enteric infection caused by bacteria belonging to the genus <it>Shigella</it>; it is clinically manifested by bloody diarrhoea. Shigellosis is endemic in many developing countries includin...

Full description

Bibliographic Details
Main Authors: Njunda Anna L, Assob Jules CN, Nsagha Dickson S, Kamga Henri LF, Awafong Maghah P, Weledji Elroy P
Format: Article
Language:English
Published: BMC 2012-01-01
Series:BMC Research Notes
Subjects:
Online Access:http://www.biomedcentral.com/1756-0500/5/54
Description
Summary:<p>Abstract</p> <p>Background</p> <p>Shigellosis is an acute invasive enteric infection caused by bacteria belonging to the genus <it>Shigella</it>; it is clinically manifested by bloody diarrhoea. Shigellosis is endemic in many developing countries including Cameroon and also occurs in epidemics causing considerable morbidity and mortality. This study evaluated the epidemiological and clinical features of <it>Shigella </it>and the resistance pattern of isolates to commonly used antibiotics in the Buea Health District in Cameroon, from April to August, 2010.</p> <p>Results</p> <p>Of the 223 stool samples cultured, 10 (4.5%) yielded <it>Shigella </it>species. Isolation rate was observed to be more in children below 15 years (7.89%), and also higher in rural areas (6.35%). All 10 isolates showed resistance to at least two antibiotics and 9 (90%) were multi-drug resistant. The highest resistance rates were encountered with cotrimoxazole (90%) and amoxicillin (80%). Least resistance was observed with azithromycin (10%).</p> <p>Conclusion</p> <p>Shigellosis is more prevalent in children below 15 years in the Buea District. There is a high level of resistance to most of the antibiotics used for the treatment of shigellosis including extended-spectrum beta-lactamases (ESBLs) as well as evidence of resistance to quinolones. Azithromycin was found to be the drug of choice for shigellosis in this setting.</p>
ISSN:1756-0500